Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
44.8 USD +1.11% Intraday chart for Avidity Biosciences, Inc. +14.87% +395.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell Small Cap Comp Value Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000 Value Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2500 Value Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 3000E Growth Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 3000 Growth Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Value Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 2000 Growth Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell Microcap Value Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000E Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000E Value Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell Microcap Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 2500 Growth Index CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell Small Cap Comp Growth Index CI
Avidity Biosciences Insider Sold Shares Worth $1,255,040, According to a Recent SEC Filing MT
Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating MT
Avidity Biosciences Prices $400.9 Million Offering of Shares MT
Avidity Biosciences Plans $300 Million Common Stock Offering MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon MT
Avidity Biosciences Shares Jump as Muscle Disease Therapy Shows Promising Early Results MT
Sector Update: Health Care MT
Top Midday Gainers MT
Chardan Raises Price Target on Avidity Biosciences to $45 From $33, Maintains Buy Rating MT
Avidity Biosciences's Muscle Disease Therapy Shows Promising Early Results -- Shares Surge Pre-Bell MT
Transcript : Avidity Biosciences, Inc. - Shareholder/Analyst Call
Chart Avidity Biosciences, Inc.
More charts
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
44.8 USD
Average target price
61.56 USD
Spread / Average Target
+37.40%
Consensus